» Articles » PMID: 21734707

Oncogene-induced Nrf2 Transcription Promotes ROS Detoxification and Tumorigenesis

Abstract

Reactive oxygen species (ROS) are mutagenic and may thereby promote cancer. Normally, ROS levels are tightly controlled by an inducible antioxidant program that responds to cellular stressors and is predominantly regulated by the transcription factor Nrf2 (also known as Nfe2l2) and its repressor protein Keap1 (refs 2-5). In contrast to the acute physiological regulation of Nrf2, in neoplasia there is evidence for increased basal activation of Nrf2. Indeed, somatic mutations that disrupt the Nrf2-Keap1 interaction to stabilize Nrf2 and increase the constitutive transcription of Nrf2 target genes were recently identified, indicating that enhanced ROS detoxification and additional Nrf2 functions may in fact be pro-tumorigenic. Here, we investigated ROS metabolism in primary murine cells following the expression of endogenous oncogenic alleles of Kras, Braf and Myc, and found that ROS are actively suppressed by these oncogenes. K-Ras(G12D), B-Raf(V619E) and Myc(ERT2) each increased the transcription of Nrf2 to stably elevate the basal Nrf2 antioxidant program and thereby lower intracellular ROS and confer a more reduced intracellular environment. Oncogene-directed increased expression of Nrf2 is a new mechanism for the activation of the Nrf2 antioxidant program, and is evident in primary cells and tissues of mice expressing K-Ras(G12D) and B-Raf(V619E), and in human pancreatic cancer. Furthermore, genetic targeting of the Nrf2 pathway impairs K-Ras(G12D)-induced proliferation and tumorigenesis in vivo. Thus, the Nrf2 antioxidant and cellular detoxification program represents a previously unappreciated mediator of oncogenesis.

Citing Articles

CBX3 promotes multidrug resistance by suppressing ferroptosis in colorectal carcinoma via the CUL3/NRF2/GPX2 axis.

Bai X, Duan T, Shao J, Zhang Y, Xing G, Wang J Oncogene. 2025; .

PMID: 40089640 DOI: 10.1038/s41388-025-03337-9.


Thirty years of NRF2: advances and therapeutic challenges.

Zhang D Nat Rev Drug Discov. 2025; .

PMID: 40038406 DOI: 10.1038/s41573-025-01145-0.


Yersiniabactin produced by promotes intestinal inflammation through lipid peroxidation and ferroptosis.

Wang H, Chen B, Xiao P, Han D, Gao B, Yan Y Front Microbiol. 2025; 16:1542801.

PMID: 40034497 PMC: 11872927. DOI: 10.3389/fmicb.2025.1542801.


The Two Faces of Reactive Oxygen Species in Cancer.

Reczek C, Chandel N Annu Rev Cancer Biol. 2025; 1:79-98.

PMID: 40034143 PMC: 11875389. DOI: 10.1146/annurev-cancerbio-041916-065808.


Recent Anti-KRAS Therapies: A "Possible Impossibility" for Pancreatic Ductal Adenocarcinoma.

Sobhani N, Pittacolo M, DAngelo A, Marchegiani G Cancers (Basel). 2025; 17(4).

PMID: 40002297 PMC: 11853620. DOI: 10.3390/cancers17040704.


References
1.
Chan K, Lu R, Chang J, Kan Y . NRF2, a member of the NFE2 family of transcription factors, is not essential for murine erythropoiesis, growth, and development. Proc Natl Acad Sci U S A. 1996; 93(24):13943-8. PMC: 19474. DOI: 10.1073/pnas.93.24.13943. View

2.
Birney E, Stamatoyannopoulos J, Dutta A, Guigo R, Gingeras T, Margulies E . Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature. 2007; 447(7146):799-816. PMC: 2212820. DOI: 10.1038/nature05874. View

3.
Wakabayashi N, Itoh K, Wakabayashi J, Motohashi H, Noda S, Takahashi S . Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. Nat Genet. 2003; 35(3):238-45. DOI: 10.1038/ng1248. View

4.
Keum Y, Yu S, Chang P, Yuan X, Kim J, Xu C . Mechanism of action of sulforaphane: inhibition of p38 mitogen-activated protein kinase isoforms contributing to the induction of antioxidant response element-mediated heme oxygenase-1 in human hepatoma HepG2 cells. Cancer Res. 2006; 66(17):8804-13. DOI: 10.1158/0008-5472.CAN-05-3513. View

5.
Suvorova E, Lucas O, Weisend C, Rollins M, Merrill G, Capecchi M . Cytoprotective Nrf2 pathway is induced in chronically txnrd 1-deficient hepatocytes. PLoS One. 2009; 4(7):e6158. PMC: 2703566. DOI: 10.1371/journal.pone.0006158. View